Your child's specialist just mentioned a clinical trial. Or an advocacy organization sent an email about a study recruiting for your child's condition. You've got a packet of information, a consent form that's thirty pages long, and a decision to make.

You want to do the right thing. But "the right thing" isn't obvious when you're being asked to enroll your child in research you don't fully understand, for a drug that may or may not work, with risks you can't fully predict. You need a framework: not a sales pitch, not a fear campaign, but a structured way to evaluate whether this trial makes sense for your family.

Here's how to think through that decision.

What Phase Is the Trial, and What Does That Mean?

Trials move through three phases before FDA approval. Each phase answers a different question.

Phase 1 tests safety in 20 to 100 people. Researchers are figuring out dosing, side effects, and whether the drug is tolerated. This is the highest-risk phase. The drug may not work at all; safety is the only question being answered.

Phase 2 tests effectiveness in 100 to 300 people. Researchers are looking for a signal that the drug does what it's supposed to do. It's still exploratory. Many drugs that pass Phase 1 fail here.

Phase 3 is large-scale confirmation, typically 1,000 to 3,000 participants or more. The drug has shown promise in earlier phases. Now the question is whether that promise holds across a bigger, more diverse group. Phase 3 trials are the final gate before FDA approval.

The phase matters because it tells you how much is already known. A Phase 1 trial means you're in the earliest group to try this drug. A Phase 3 trial means hundreds of people have already taken it, and you're helping confirm what researchers already believe is true.

Neither is inherently better. But you need to know which category you're in.

Randomization Means You Might Not Get the Drug

Many trials are randomized. You enroll, and your child is assigned to either the active drug group or the placebo group. Double-blind means neither you nor the investigator knows which group your child is in until the trial ends.

This is scientifically necessary, but it's also a practical reality you need to account for. If your primary reason for enrolling is access to the drug, and your child ends up in the placebo group, you've spent months on trial logistics without that access.

Some trials offer an open-label extension after the blinded phase ends. That means everyone gets the active drug once the randomized portion is complete. Ask whether that's part of the design. If it's not, and your child was randomized to placebo, you leave the trial with data contributed but no treatment received.

Three Categories of Risk You Should Evaluate

Risk isn't just "adverse events." It's broader than that.

Therapeutic risk is what most people think of first: side effects, adverse reactions, unknown long-term effects. Ask the investigator what the most common side effects have been in earlier phases. Ask what the serious adverse event rate is. Ask what happens if your child has a reaction: does the trial stop, or does your child just exit while the trial continues?

Practical risk is disruption to your family. Trials require visits, sometimes weekly or monthly. They require bloodwork, imaging, cognitive testing. Some require travel to a specialized site. Some require your child to stop other therapies during the trial period. Add up what this looks like in your family's schedule and your child's routine. That's a real cost, even if the trial covers medical expenses.

Opportunity cost is the hardest to assess. If your child is in a trial, they may not be eligible for other trials running at the same time. If the trial requires stopping a therapy that's currently helping, you're trading a known benefit for an unknown one. Some families enroll because they've tried everything else and this is the only option left. Some families enroll when their child is stable, and the trial puts that stability at risk. Know which situation you're in.

You Have Rights, and You Should Know Them

Clinical trial participation is voluntary. That's not just a legal statement; it's the foundation of every right you have in this process.

You have the right to withdraw at any time, for any reason, without penalty to your child's care. If the trial is being conducted through your child's regular medical team, withdrawal does not affect your child's access to standard care. You don't owe an explanation, though investigators will ask for one.

You have the right to receive standard care even if your child is removed from the trial, whether you withdrew or the investigator removed them due to an adverse event. The trial protocol should specify this. If it doesn't, ask.

You have the right to see study results after the trial concludes. Many trials publish results in academic journals, but not all. Ask the investigator how and when results will be shared with participants. If the trial is listed on ClinicalTrials.gov (all U.S. trials must be), you can check back for posted results after the trial ends.

Informed consent is a process, not just a document. You can ask questions at any point: before enrollment, during the trial, after an adverse event. If something changes in your child's health or your family's situation, you can revisit the decision. Signing the consent form doesn't lock you in.

How to Evaluate the Investigator and the Site

Not all trial sites are equally experienced, and not all investigators have the same track record. You can check.

Go to ClinicalTrials.gov and search for the investigator's name or the site. Look at how many trials they've completed versus how many they've started. Sites that routinely complete trials tend to have better infrastructure, better communication, and more realistic enrollment timelines. Sites that have several trials listed as "terminated" or "withdrawn" may have organizational or funding issues.

Check whether the trial has current IRB (Institutional Review Board) approval. Every trial must have it. The IRB is the ethics oversight body that reviews the trial design, consent process, and participant protections. You can ask the investigator for the IRB approval status. If they hesitate or can't provide it, that's a red flag.

Look at the primary endpoint listed on ClinicalTrials.gov. That's the main outcome the trial is designed to measure. If the primary endpoint is something that matters to you (improved motor function, reduced seizure frequency, cognitive gains), the trial is designed around outcomes you care about. If the primary endpoint is a biomarker you've never heard of and don't understand, ask the investigator to explain why that marker matters for your child's day-to-day life.

Connect With Families Who've Been Through It

Clinical trial decisions aren't made in a vacuum. Other families have enrolled in trials for your child's condition, and many of them are willing to talk about it.

Condition-specific advocacy organizations often have trial liaison staff or peer networks. FRAXA Research Foundation, for example, connects Fragile X families considering trials with families who've already participated. Many rare disease foundations offer similar resources.

Parent-to-parent networks give you access to questions you didn't know to ask. Families who've been through a trial can tell you what the visit schedule felt like, whether the investigator was responsive when problems came up, whether the trial covered all costs or whether there were surprise expenses, and whether they felt the decision was worth it in hindsight.

You're not looking for someone to tell you what to decide. You're looking for someone who can describe what the experience was like, so you can imagine your family in it.

What to Ask Before You Decide

These are the questions that help you evaluate whether this trial makes sense for your child and your family.

• What phase is the trial, and what question is it designed to answer?
• Is the trial randomized? Is there a placebo group? Is there an open-label extension?
• What are the most common side effects from earlier phases? What are the serious adverse events?
• What happens if my child has a reaction? Do they exit the trial, or does the trial pause?
• Can we withdraw at any time? What happens to my child's care if we do?
• How many visits are required, and where? What does each visit involve?
• Does my child need to stop any current therapies to participate?
• Who covers costs: travel, lodging, missed work, medical expenses not covered by the trial?
• How will results be shared with participants?
• Has this site completed other trials? Can I see the IRB approval status?

Write the answers down. If the investigator can't answer a question, or if the answer changes when you ask again later, that's information.

Children Have Additional Protections Under Federal Law

Pediatric trials are subject to stricter oversight than adult trials. Under federal regulations (45 CFR 46 Subpart D), trials involving children must meet one of these criteria: the trial offers the prospect of direct benefit to the child, or the trial involves no more than minimal risk and is likely to yield generalizable knowledge about the child's condition.

If a trial does not offer direct benefit (for example, if it's purely observational or involves only biomarker collection), it must demonstrate minimal risk. The IRB reviews this before approving the trial. You don't need to interpret the regulation yourself, but you should know it exists. If a trial feels like it's asking a lot of your child without offering them a meaningful shot at benefit, ask the investigator how the trial was justified under Subpart D.

When to Say No

Some families enroll because it's the only option left. Some enroll because they want to contribute to science even if their child doesn't benefit directly. Some enroll because the trial offers access to a drug they can't get any other way.

But enrollment isn't always the right call.

If the practical demands of the trial would destabilize your family or your child's routine in ways that outweigh the potential benefit, it's reasonable to say no. If the investigator can't answer your questions, or if the trial site has a weak track record, it's reasonable to say no. If your child is doing well on their current treatment plan and the trial requires stopping that treatment, it's reasonable to ask whether this is the right time.

You're allowed to prioritize stability. You're allowed to prioritize your family's capacity. You're allowed to decide that the unknowns outweigh the potential upside.

The decision is yours. Not the investigator's, not the advocacy organization's, not the other families who've enrolled. The framework is the same for everyone. The answer is different for every family.